1. Y. Shiokawa, Y. Horiuchi, Y. Mizushima, T. Kageyama, K. Shichikawa, T. Ofuji, M. Honma, H. Yoshizawa, C. Abe and N. Agawa,A multicenter double-blind controlled study of lobenzarit, a novel immunomodulator, in rheumatoid arthritis. J. Rheumatol.11, 615–623 (1984).
2. Y. Shiokawa, Y. Mizushima, K. Shichikawa, M. Nobunaga, M. Honma, H. Yoshizawa and C. Abe,Effect of lobenzarit disodium (CCA) against the abnormal immunological parameters in rheumatoid arthritis. Int. J. Immunotherapy3, 213–222 (1987).
3. Y. Ohsugi, S. Hata, M. Taneumura, T. Nakano, T. Matsuno, Y. Takagaki, Y. Nishii and M. Shindo,N-(2-carboxyphenyl)-4-choroantranilic acid disodium salt: a novel anti-arthritic agent without antiinflamatory and immunosuppressive activities. J. Pharm. Pharmac.29, 636–637 (1977).
4. Y. Ohsugi, T. Nakano and S. Hata,A novel antiarthritic agent, CCA (lobenzarit disodium), and the role of thymus derived lymphocytes in the inhibition of rat adjuvant arthritis. Immunopharmacology6, 15–21 (1983).
5. T. Nakano, Y. Yamashita, Y. Ohsugi, Y. Sugawara, S. Hata and Y. Takagaki,The effect of CCA (lobenzarit disodium) on the suppressor T-cell function and the production of autoantibodies in New Zealand Black and New Zealand White F1 mice. Immunopharmacology5, 293–302 (1983).